S14 Ep16: Establishing the Rationale for ADC and ICI Combinations in TNBC

from OncLive® On Air · host OncLive® On Air

In this podcast, experts Virginia Kaklamani, MD, DSc, and Tiffany A. Traina, MD, FASCO, discuss the rationale for and data to support combining TROP2-targeting antibody-drug conjugates (ADCs) with immune checkpoint inhibitors (ICIs) to treat triple-negative breast cancer (TNBC).

Episode metadata supplied by the publisher feed · Published Sep 16, 2025

Embed this episode

Attribution link and audio player

NOW PLAYING

S14 Ep16: Establishing the Rationale for ADC and ICI Combinations in TNBC

0:00 18:30

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of OncLive® On Air?

This episode is 18 minutes long.

When was this OncLive® On Air episode published?

This episode was published on September 16, 2025.

Can I download this OncLive® On Air episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!